State Ledger
Company profile

Aldeyra Therapeutics, Inc. CIK 1341235

Ticker
ALDX (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Lexington, MA 02421
Fiscal year end
2025 (FY)
Market Data
Close
$0.91
Change
-$0.02
Change %
-2.52%
Volume
37,164

ALDX · trading date Oct 12, 2026 · previous close $0.93 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$33.85M
Total assets
$72.06M
Total liabilities
$27.81M
Stockholders' equity
$44.25M
Cash & equivalents
$70.04M
Operating income
-$35.27M
Operating cash flow
-$33.35M
Capital expenditures
—

Fiscal year 2025, via 10-K filed 2026-02-27. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
38.6%
Equity / assets
61.4%
CapEx / revenue
—
Operating cash flow / net income
0.99×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$33.85M $72.06M $27.81M $44.25M
2024 — -$55.85M $104.61M $33.60M $71.00M
2023 — -$37.54M $148.33M $28.53M $119.80M
2022 — -$62.02M $181.29M $30.28M $151.01M
2021 — -$57.78M $233.14M $27.40M $205.74M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form SCHEDULE 13G
2026-08-12
Financials filed via
Form 10-K
filed 2026-02-27

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Lexington, MA 02421
131 HARTWELL AVENUE
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:34 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Massachusetts — Public Companies